Dry powder inhaler and system for drug delivery

Patent metadata

Field	Value
Publication number	US-11241549-B2
Application number	US-201916271585-A
Country	US
Kind code	B2
Filing date	Feb 8, 2019
Priority date	Jun 13, 2008
Publication date	Feb 8, 2022
Grant date	Feb 8, 2022

Abstract

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

First claim

We claim:

1. An inhaler comprising:
a mouthpiece;
an outer shell; and
a sled including a cartridge holder configured to hold a cartridge including a container and a top, wherein the top comprises at least one dispensing port, wherein the container is configured to move relative to the top;
wherein the outer shell is in a telescopic arrangement with the mouthpiece, and wherein actuation of the outer shell relative to the mouthpiece is configured to translationally move the sled thereby moving the container relative to the top from a containment position to a dosing position and then a further actuation of the outer shell relative to the mouthpiece is configured to translationally move the sled thereby moving the container relative to the top from the dosing position towards containment position.

2. The inhaler of claim 1 , wherein movement of the sled is configured to translocate the container.

3. The inhaler of claim 2 , comprising a housing to accommodate the container.

4. The inhaler of claim 3 , wherein the container is configured to house a dry powder medicament including at least one active ingredient.

5. The inhaler of claim 4 , wherein the at least one active ingredient is a peptide, polypeptide, protein, or a combination thereof.

6. The inhaler of claim 4 , wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, an argatroban, anti-SSX-2 41-49 , anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

7. The inhaler of claim 4 , wherein the dry powder medicament comprises a diketopiperazine.

8. The inhaler of claim 7 , wherein the diketopiperazine is

9. An inhaler comprising:
a mouthpiece;
an outer shell; and
a sled including a cartridge holder configured to interface with a container and a top, wherein the top comprises at least one dispensing port, wherein the container is configured to move relative to the top;
wherein the outer shell is in a telescopic arrangement with the mouthpiece, and wherein actuation of the outer shell relative to the mouthpiece moves the sled to translocate a cartridge in the cartridge holder relative to the top from a containment position to a dosing position and then a further actuation of the outer shell relative to the mouthpiece is configured to translationally move the sled thereby moving the container relative to the top from the dosing position towards containment position then an opposite movement moves the container back toward the containment position, and
wherein in the dosing position 10% to 70% of total airflow through the inhaler enters and exits the cartridge.

10. The inhaler of claim 9 , wherein the container is configured to house a dry powder medicament.

11. The inhaler of claim 10 , wherein the dry powder medicament includes at least one active ingredient.

12. The inhaler of claim 11 , wherein the at least one active ingredient is a peptide, polypeptide, protein, or a combination thereof.

13. The inhaler of claim 11 , wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, an argatroban, anti-SSX-2 41-49 , anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

14. The inhaler of claim 11 , wherein the dry powder medicament comprises a diketopiperazine.

15. The inhaler of claim 14 , wherein the diketopiperazine is

16. An inhaler comprising:
a mouthpiece;
an outer shell; and
a sled including a cartridge holder configured to hold a cartridge including a container and a top, wherein the top comprises at least one dispensing port, wherein the container is configured to move relative to the top;
wherein the outer shell is in a telescopic arrangement with the mouthpiece, and wherein actuation of the outer shell relative to the mouthpiece is configured to translationally move the sled along tracks thereby moving the container relative to the top from a containment position to a dosing position and then a further actuation of the outer shell relative to the mouthpiece is configured to translationally move the sled thereby moving the container relative to the top from the dosing position towards containment position then an opposite movement moves the container back toward the containment position.

17. The inhaler of claim 16 , wherein movement of the sled is configured to translocate the cartridge container.

18. The inhaler of claim 17 , comprising a housing to accommodate the container.

19. The inhaler of claim 18 , wherein the container is configured to house a dry powder medicament including at least one active ingredient.

20. The inhaler of claim 19 , wherein the at least one active ingredient is a peptide, polypeptide, protein, or a combination thereof.

21. The inhaler of claim 19 , wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, an argatroban, anti-SSX-2 41-49 , anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

22. The inhaler of claim 19 , wherein the dry powder medicament comprises a di ketopiperazine.

23. The inhaler of claim 22 , wherein the diketopiperazine is

Assignees

• Mannkind Corp

Inventors

• Smutney Chad C
• Kinsey P Spencer
• Sahi Carl R
• Adamo Benoit
• Polidoro John M
• Mclean Scott
• Overfield Dennis
• Bryant Anthony

Classifications

• A61M15/0028 Primary

  using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up · CPC title

• A61M15/0023

  retractable · CPC title

• A61M2205/6081

  Colour codes · CPC title

• A61M2206/20

  having means for promoting or enhancing the flow, actively or passively · CPC title

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title